News headlines about Biocept (NASDAQ:BIOC) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biocept earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 45.4828451568562 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Biocept (NASDAQ:BIOC) opened at $0.30 on Wednesday. Biocept has a 52 week low of $0.26 and a 52 week high of $2.75. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.27 and a current ratio of 1.41.
BIOC has been the subject of a number of analyst reports. Zacks Investment Research raised Biocept from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a research report on Monday, January 15th. Chardan Capital reaffirmed a “buy” rating and set a $1.50 price objective (down previously from $2.50) on shares of Biocept in a research report on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $1.75.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/21/biocept-bioc-earning-somewhat-favorable-news-coverage-report-finds.html.
Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.